The Safety of Continuous Infusion Propofol in Mechanically Ventilated Adults With Coronavirus Disease 2019
| Autor: | Corey J. Witenko, Audrey J. Littlefield, Sajjad Abedian, Anjile An, Philip S. Barie, Karen Berger |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Adult
adverse drug reactions SARS-CoV-2 sedatives respiratory failure COVID-19 Research Reports 030208 emergency & critical care medicine Respiration Artificial critical care Intensive Care Units 03 medical and health sciences 0302 clinical medicine Pancreatitis Acute Disease Humans Pharmacology (medical) 030212 general & internal medicine Propofol Retrospective Studies |
| Zdroj: | The Annals of Pharmacotherapy |
| ISSN: | 1542-6270 1060-0280 |
| Popis: | Background: Propofol is commonly used to achieve ventilator synchrony in critically ill patients with coronavirus disease 2019 (COVID-19), yet its safety in this patient population is unknown. Objective: To evaluate the safety, in particular the incidence of hypertriglyceridemia, of continuous infusion propofol in patients with COVID-19. Methods: This was a retrospective study at 1 academic medical center and 1 affiliated teaching hospital in New York City. Adult, critically ill patients with COVID-19 who received continuous infusion propofol were included. Patients who received propofol for Results: A total of 252 patients were included. Hypertriglyceridemia (serum triglyceride concentration ≥ 400 mg/dL) occurred in 38.9% of patients after a median cumulative dose of 4307 mg (interquartile range [IQR], 2448-9431 mg). The median time to triglyceride elevation was 3.8 days (IQR, 1.9-9.1 days). In the multivariable regression analysis, obese patients had a significantly greater odds of hypertriglyceridemia (odds ratio = 1.87; 95% CI = 1.10, 3.21). There was no occurrence of acute pancreatitis. The incidence of possible propofol-related infusion syndrome was 3.2%. Conclusion and Relevance: Hypertriglyceridemia occurred frequently in patients with COVID-19 who received propofol but did not lead to acute pancreatitis. Elevated triglyceride concentrations occurred more often and at lower cumulative doses than previously reported in patients without COVID-19. Application of these data may aid in optimal monitoring for serious adverse effects of propofol in patients with COVID-19. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|